Argos Therapeutics Inc (NASDAQ:ARGS) had its target price reduced by Stifel Nicolaus to $1.20 in a research report sent to investors on Friday morning. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC cut shares of Argos Therapeutics from a buy rating to a hold rating in a report on Wednesday, February 22nd. FBR & Co restated a hold rating on shares of Argos Therapeutics in a report on Thursday, February 23rd. JMP Securities cut shares of Argos Therapeutics from an outperform rating to a market perform rating in a report on Wednesday, February 22nd. Finally, Zacks Investment Research upgraded shares of Argos Therapeutics from a hold rating to a buy rating and set a $6.00 price target for the company in a report on Monday, January 16th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $8.03.
Shares of Argos Therapeutics (NASDAQ:ARGS) traded down 18.7600% on Friday, reaching $0.8124. 763,970 shares of the company traded hands. Argos Therapeutics has a 52-week low of $0.75 and a 52-week high of $13.97. The stock’s market cap is $33.51 million. The stock has a 50 day moving average of $2.93 and a 200 day moving average of $4.34.
Your IP Address:
Several hedge funds and other institutional investors have recently made changes to their positions in ARGS. State Street Corp raised its position in shares of Argos Therapeutics by 11.7% in the fourth quarter. State Street Corp now owns 177,494 shares of the biopharmaceutical company’s stock worth $870,000 after buying an additional 18,625 shares in the last quarter. Sanders Morris Harris Inc. raised its position in shares of Argos Therapeutics by 109.9% in the third quarter. Sanders Morris Harris Inc. now owns 241,512 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 126,475 shares in the last quarter. Finally, Wasatch Advisors Inc. raised its position in shares of Argos Therapeutics by 35.2% in the third quarter. Wasatch Advisors Inc. now owns 3,228,741 shares of the biopharmaceutical company’s stock worth $16,047,000 after buying an additional 840,260 shares in the last quarter. 15.25% of the stock is owned by institutional investors and hedge funds.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.